Aprea Therapeutics Statistics
Share Statistics
Aprea Therapeutics has 5.53M
shares outstanding. The number of shares has increased by 1.14%
in one year.
| Shares Outstanding | 5.53M |
| Shares Change (YoY) | 1.14% |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | 0.02% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,298 |
| FTD / Avg. Volume | 16.95% |
Short Selling Information
The latest short interest is 59.98K, so 1.09% of the outstanding
shares have been sold short.
| Short Interest | 59.98K |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 3.07 |
Valuation Ratios
The PE ratio is -1.4 and the forward
PE ratio is -1.12.
Aprea Therapeutics's PEG ratio is
0.03.
| PE Ratio | -1.4 |
| Forward PE | -1.12 |
| PS Ratio | 12.06 |
| Forward PS | 0.1 |
| PB Ratio | 0.94 |
| P/FCF Ratio | -1.34 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aprea Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.01,
with a Debt / Equity ratio of 0.
| Current Ratio | 7.01 |
| Quick Ratio | 7.01 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $187,822.62 |
| Profits Per Employee | $-1,619,838.88 |
| Employee Count | 8 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -69.25% in the
last 52 weeks. The beta is 1.19, so Aprea Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -69.25% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 46.97 |
| Average Volume (20 Days) | 25,353 |
Income Statement
In the last 12 months, Aprea Therapeutics had revenue of 1.5M
and earned -12.96M
in profits. Earnings per share was -2.35.
| Revenue | 1.5M |
| Gross Profit | 1.48M |
| Operating Income | -14.32M |
| Net Income | -12.96M |
| EBITDA | -12.94M |
| EBIT | -12.96M |
| Earnings Per Share (EPS) | -2.35 |
Full Income StatementBalance Sheet
The company has 22.85M in cash and 0 in
debt, giving a net cash position of 22.85M.
| Cash & Cash Equivalents | 22.85M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -321.04M |
| Total Assets | 20.22M |
| Working Capital | 16.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -13.56M
and capital expenditures -15.48K, giving a free cash flow of -13.57M.
| Operating Cash Flow | -13.56M |
| Capital Expenditures | -15.48K |
| Free Cash Flow | -13.57M |
| FCF Per Share | -2.46 |
Full Cash Flow StatementMargins
Gross margin is 98.51%, with operating and profit margins of -953% and -862.43%.
| Gross Margin | 98.51% |
| Operating Margin | -953% |
| Pretax Margin | -862.43% |
| Profit Margin | -862.43% |
| EBITDA Margin | -860.94% |
| EBIT Margin | -953% |
| FCF Margin | -903.26% |
